You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

Citation Tools

Article menu

Download PDFPDF

XML
Research Article
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Shitara K, Satoh T, Iwasa S, et al
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer 2019;7:219. doi: 10.1186/s40425-019-0679-9